INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46m ago
HOUSE PTR6m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Public company

NRIXNurix Therapeutics, Inc.

CIK 0001549595

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 16
Max Insider Score35
Connections6with evidence

NRIX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$29K
1,075 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Saltzman Edward CDirector · May 15, 2026
  • ← Insider ofevidence
    Hansen GwennChief Scientific Officer · Jan 30, 2026
  • ← Insider ofevidence
    van Houte HansChief Financial Officer · Jan 30, 2026
11
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$24K
1,469 sh
Nov 4, 2026
Nov 4, 2026
traded Nov 4, 2026
+0d
SEC FORM 4

Evidence

18
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$51K
3,300 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

23
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$158K
6,113 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC FORM 4

Evidence

0
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,786 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
5,786 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

19
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$245K
9,527 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

14
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

10
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

6
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

11
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$104K
3,957 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

8
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$39K
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

4
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Nov 2, 2026Nov 2, 2026
traded Nov 2, 2026
+0dSEC FORM 4

Evidence

13
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

35
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$104K
3,957 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

10
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

10
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,859 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

34
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$74K
2,834 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

17
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,573 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

10
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Oct 30, 2026Nov 2, 2026
traded Oct 30, 2026
+3dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

1
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Oct 15, 2026Oct 15, 2026
traded Oct 15, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

0
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,701
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

1
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
1,452 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

0
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
13.3K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

21
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$581K
28.9K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

9
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
5,394 sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

7
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$97K
13.3K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

7
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$136K
15.6K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

0
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.6K sh
Jun 25, 2026Jun 25, 2026
traded Jun 25, 2026
+0dSEC FORM 4

Evidence

9
SC
Saltzman Edward CDirector
NRIXNurix Therapeutics, Inc.
Grant or award
A—
31.3K sh
May 15, 2026May 15, 2026
traded May 15, 2026
+0dSEC FORM 4

Evidence

15
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$90K
5,394 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

13
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

31
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$53K
3,214 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

2
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

10
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

6
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

6
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

6
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

6
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

13
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,000 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

27
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Open-market sale
SELL$40K
2,388 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

9
VH
van Houte HansChief Financial Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
2,858 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

5
HG
Hansen GwennChief Scientific Officer
NRIXNurix Therapeutics, Inc.
Option exercise
M—
3,750 sh
Apr 30, 2026Apr 30, 2026
traded Apr 30, 2026
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Ring ChristineChief Legal Officer · Nov 24, 2025
  • ← Insider ofevidence
    Dansey Roger DDirector · Nov 10, 2025